Pfizer Blames Fesoterodine Partner Schwarz For Launch Delay
This article was originally published in The Pink Sheet Daily
Executive Summary
The company anticipates the incontinence therapy will launch in early 2009, nearly two years later than expected.
You may also be interested in...
Pfizer Toviaz Clears FDA For OAB: Three-Year Window To Establish Detrol Successor
Anti-muscarinic agent acquired from Schwarz in 2006 to hit U.S. market in 2009; in time to build sales before Pfizer’s Detrol goes off-patent in 2012.
Pfizer Toviaz Clears FDA For OAB: Three-Year Window To Establish Detrol Successor
Anti-muscarinic agent acquired from Schwarz in 2006 to hit U.S. market in 2009; in time to build sales before Pfizer’s Detrol goes off-patent in 2012.
Pfizer To Acquire Urology Agent Fesoterodine From Schwarz
The deal also ends a patent dispute regarding fesoterodine and Pfizer's incontinence agent Detrol.